NCT00001193 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Buzdar AU, Montague ED, Barker JL, Hortobagyi GN, Blumenschein GR
Management of inflammatory carcinoma of breast with combined modality approach - an update. Cancer. 1981 Jun 1;47(11):2537-42.
Chu AM, Wood WC, Doucette JA
Inflammatory breast carcinoma treated by radical radiotherapy. Cancer. 1980 Jun 1;45(11):2730-7.
McElwain TJ, Hedley DW, Gordon MY, Jarman M, Millar JL, Pritchard J
High dose melphalan and non-cryopreserved autologous bone marrow treatment of malignant melanoma and neuroblastoma. Exp Hematol. 1979;7 Suppl 5:360-71.

A Multimodality Treatment Approach to Patients With Inflammatory Cancer of the Breast and Locally Advanced Non-Inflammatory Stage III Breast Cancer and Stage IV Breast Cancer

Details for clinical trial NCT00001193

Clinical trial NCT00001193 - References